- ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia
- ERYTECH to Present at JMP Securities Life Science Conference
- ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018
- Erytech Pharma S.A. : General Meeting to be held on June 28, 2018 and Availability of Related Materials
- ERYTECH to Present Pharmacodynamic Data from Phase 2/3 Trial of Eryaspase in ALL at ASCO 2018
Erytech Pharma SA (ERYP:PAR) closed at 9.54, 5.76% above its 52-week low of 9.02, set on Jul 04, 2018.
9.02Jul 04 201829.70Oct 12 2017
Markit short selling activity
|Market cap||168.79m EUR|
|EPS (TTM)||-2.94 |
Data delayed at least 15 minutes, as of Jul 16 2018 16:35 BST.